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Abstract
Background Primary or metastatic osseous and soft tissue
lesions can be treated by ablation techniques.
Methods These techniques are classified into chemical abla-
tion (including ethanol or acetic acid injection) and thermal
ablation (including laser, radiofrequency, microwave,
cryoablation, radiofrequency ionisation and MR-guided
HIFU). Ablation can be performed either alone or in combi-
nation with surgical or other percutaneous techniques.
Results In most cases, ablation provides curative treatment for
benign lesions and malignant lesions up to 3 cm. Furthermore,
it can be a palliative treatment providing pain reduction and
local control of the disease, diminishing the tumour burden
and mass effect on organs. Ablation may result in bone
weakening; therefore, whenever stabilisation is undermined,
bone augmentation should follow ablation depending on the
lesion size and location.
Conclusion Thermal ablation of bone and soft tissues demon-
strates high success and relatively low complication rates.
However, the most common complication is the iatrogenic
thermal damage of surrounding sensitive structures. Nervous
structures are very sensitive to extremely high and low tem-
peratures with resultant transient or permanent neurological
damage. Thermal damage can cause normal bone
osteonecrosis in the lesion’s periphery, surrounding muscular
atrophy and scarring, and skin burns. Successful thermal
ablation requires a sufficient ablation volume and thermal
protection of the surrounding vulnerable structures.
Teaching points
• Percutaneous ablations constitute a safe and efficacious
therapy for treatment of osteoid osteoma.
•Ablation techniques can treat painful malignantMSK lesions
and provide local tumour control.
• Thermal ablation of bone and soft tissues demonstrates high
success and low complication rates.
• Nerves, cartilage and skin are sensitive to extremely high
and low temperatures.
• Successful thermal ablation occasionally requires thermal
protection of the surrounding structures.
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Introduction
During the last decades, technological evolution in the fields
of both imaging and instrumentation has led to the develop-
ment of minimally invasive percutaneous ablative techniques
for the treatment of benign and malignant bone tumours.
Nowadays, percutaneous ablation techniques in the musculo-
skeletal system include chemical ablation (i.e. injection of
ethanol, acetic acid), irreversible electroporation (IRE) and
thermal ablation [radiofrequency ablation (RFA), microwave
ablation (MWA), cryoablation] [1–11]. In the latter tech-
niques, one should also include coblation (radiofrequency
ionisation used mainly for tumour decompression), irrevers-
ible electroporation (IRE) and MR-guided HIFU (high inten-
sity focus ultrasound, which is totally noninvasive). These
techniques may act as first-line therapies in certain
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pathological entities or as attractive adjuncts to conservative
therapy, radiotherapy or surgery in other cases.
Prior to performing any ablation, the interventional radiol-
ogist should be aware of the tumour histology (benign or
malignant), the patient’s general condition and the degree of
bone destruction (will consolidation be needed?) [2]. The final
decision for malignant cases is made by multidisciplinary
oncologic boards. The aim of the ablation (curative versus
palliative) should be precisely defined from the beginning of
the strategy planning. According to the standards of practice
for bone ablation, indications for curative treatments include
benign (osteoid osteoma, osteoblastoma <3 cm in diameter,
chondroblastoma) and malignant (slow-growing cancers with
<3 lesions of <3 cm in diameter each) lesions [2]. Indications
for palliative therapies include pain reduction, tumour
debulking, decompression and reduction and/or prevention
of impeding pathological fractures (where stabilisation will
be necessary in combination with the ablation technique)
[1–11].
This article will describe the mechanism of action of dif-
ferent ablative technologies applied to the musculoskeletal
system, summarise the data concerning the safety and effec-
tiveness of percutaneous ablation techniques for benign and




Ablation in the musculoskeletal system can be quite painful
and should be performed under some kind of anaesthesia,
ranging from conscious sedation to general anaesthesia. All
procedures are performed under extensive local sterility mea-
sures and prophylactic antibiotics. Whenever an intact bone
cortex is noted the coaxial approach is required; the trocar is
either drilled or hammered through the cortex depending on
the type of cortical reaction (lytic vs. blastic). Once in position,
the needle is removed from the trocar and the ablation instru-
ment is inserted coaxially. It is recommended to pass through
the lesion before placing the probe, as the sensitive tip of the
ablation probe could be damaged by trying to force it through
the lesion. Always remember to move the trocar away from
the expected ablation zone in order to avoid having a conduc-
tor that will transmit heat from the lesion to the surface, with
resultant skin and soft tissues burns. In addition, extreme care
should be taken concerning the surrounding structures, espe-
cially those sensitive to heat or cold (e.g. nerves). Heating at
45˚C has been shown to be neurotoxic to spinal cord and
peripheral nerves [12–14]. Cryoablation can also cause neural
damage with temporary neuropraxia occurring at −20˚C and
permanent neurological damage at ≤−40˚C [2]. Protective
measures include passive thermal protection techniques (ther-
mocouples for temperature monitoring, intraoperative neuro-
logical monitoring systems such as neurodiagnostic EEG,
EMG and evoked potential electrodes and accessories) or
active thermal protection techniques (skin protection,
hydrodissection, CO2 or air insulation) [2, 15].
Ethanol ablation Access is gained to the lesion through a
percutaneously placed needle. Ethanol injection causes cellu-
lar dehydration, vascular thrombosis and ischaemia; however,
the technique is governed by the disadvantage of unpredict-
able diffusion [8].
Laser ablation Lasers [neodymium yttrium aluminum garnet
(Nd:YAG) diode laser 800–1,000 nm] are coaxially inserted in
the tumour and transmit infra-red light energy, which results in
protein denaturation and coagulation necrosis [2, 8].
Concerning active protective techniques, gas dissection can
be performed with air or CO2 (CO2 is more soluble and a
better insulator than air; it is therefore more commonly pre-
ferred), hydrodissection is performed with dextrose 5 % (acts
as an insulator as opposed to normal saline, which acts as a
conductor). All kinds of skin cooling, thermal and neural
monitoring can be performed.
Radiofrequency ablation Straight or expandable percutane-
ously placed electrodes deliver a high-frequency alternating
current, which causes ionic agitation with resultant frictional
heat (temperatures of 60–100 ˚C) that produces protein dena-
turation and coagulation necrosis [8]. Concerning active pro-
tective techniques, all kinds of gas dissection can be per-
formed. Hydrodissection is performed with dextrose 5 % (acts
as an insulator as opposed to normal saline, which acts as a
conductor). All kinds of skin cooling, thermal and neural
monitoring can be performed.
Microwave ablation Straight percutaneously placed antennae
deliver electromagnetic microwaves (915 or 2,450 MHz) with
resultant frictional heat (temperatures of 60–100 ˚C) that
produces protein denaturation and coagulation necrosis [8].
Concerning active protective techniques, all kinds of gas
dissection can be performed, whilst hydrodissection is usually
avoided (MWA is based on agitation of water molecules for
energy transmission). All kinds of skin cooling, thermal and
neural monitoring can be performed.
Cryoablation Straight percutaneously placed cryoprobes de-
liver room temperature argon gas (for cooling) and helium gas
(for thawing) with two cycles of 10-min freezing separated by
a 5-min cycle of active thawing usually constituting a typical
ablation session [8]. An advantage of cryoablation is that the
ice ball is visible under imaging guidance. Also, the technique
is governed by significantly lower peri- and post-procedural
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pain [5]. Disadvantages include the increased cost and time
duration [6]. Concerning active protective measures, all kinds
of gas dissection can be performed; however, hydrodissection
is contraindicated since fluid will freeze when in contact with
the ice ball. All kinds of skin warming, thermal and neural
monitoring can be performed.
MR-guided HIFU Focussed ultrasound energy is delivered
within the lesion under MR guidace with resultant focal
elevated temperatures [8]. An advantage of the technique is
the real-time thermal monitoring provided by the MR guid-
ance. MR-guided HIFU sessions are performed with a fo-
cussed ultrasound phased-array system for treatment, which
is integrated with the MR system. Patients are placed in the
optimal position to align the lesion to be treated with the
ultrasound transducer located in the MR table. The transducer
is housed in an oil bath located in the MR table; a moistened
gel pad is used to couple the transducer to the patient’s skin
and to eliminate air across the path of the ultrasound beam.
Treatment planning is three-dimensional, including a combi-
nation of coronal, sagittal and axial sequences with and with-
out fat suppression. In addition, treatment planning takes
account of the anticipated energy delivered through the skin
to the target lesion. Low subtherapeutic sonications can be
used to verify the correct target area and then treatment starts
at full therapeutic power.
Irreversible Electroporation (IRE) Each cell membrane point
has a local transmembrane voltage that determines a dynamic
phenomenon called electroporation (reversible or irreversible)
[16]. Electroporation is manifested by specific transmembrane
voltage thresholds related to a given pulse duration and shape.
Thus, a threshold for an electronic field magnitude is defined
and only cells with higher electric field magnitudes than this
threshold are electroporated. IRE produces persistent nano-
sized membrane pores compromising the viability of cells
[16]. On the other hand, collagen and other supporting struc-
tures remain unaffected. The IRE generator produces direct
current (25–45 A) electric pulses of high voltage (1,500–
3,000 V).
Benign tumours
Osteoid osteoma is a relatively common benign tumour (2-
3 % of all bone tumours, 10 % of benign bone tumours)
usually seen in children and young adults [17]. Although these
small tumours (usually of <1.5 cm diameter) have no or a
minimum growth rate, they seem larger in imaging studies
because of the surrounding oedema and tissue reaction [17].
Due to the extreme appearance of the surrounding tissues,
MRI usually leads to overestimation and occasionally is mis-
leading for the diagnosis; CTseems to be the method of choice
for the diagnosis of osteoid osteoma [18]. This benign tumour
is quite painful and patients complain of localised pain that is
worse in the night and characteristically relieved by NSAIDs
(nonsteroid antiinflammatory drugs) [6]. In the literature there
are few studies with limited patient numbers reporting disap-
pearance of the pain after conservative therapy even if the
imaging findings stay the same with no changes [19–21].
Before deciding to try to treat an osteoid osteoma conserva-
tively, the physician should weigh the potential complications,
including not only those from long-term use of NSAIDs but
also the chance of muscular atrophy and bone deformity in
patients aged <5 years [6, 22].
Radiofrequency ablation was first performed in oste-
oid osteoma [23, 24]. Ever since, for the therapy of this
benign tumour, thermal ablation constitutes a first-line
therapy. Concerning osteoid osteoma ablation, through-
out the literature there are numerous studies, some with
smaller and others with higher numbers of patients, but
all of them have quite high pain reduction rates (up to
96 %) and low recurrence rates (∼7 % at 2 years) in
common [6, 25–31]. Described thermal ablation tech-
niques for the treatment of osteoid osteoma include the
use of monopolar or bipolar RF electrodes, plasma-
mediated RF electrodes and laser [32–36]. Recent stud-
ies on the use of microwaves and MR-guided HIFU
report similar success rates and minimal complications
[37–39].
Percutaneous ablation of osteoid osteoma is performed
under CT guidance, extended local sterility measures and
antibiotic prophylaxis. Access to the nidus is achieved with
a trocar that is either hammered or drilled through the intact
bone. Once inside the nidus, a bone biopsy needle can be
inserted coaxially and a sample obtained to verify the osteoma
diagnosis. Then the electrode is inserted coaxially through the
trocar, and ablation is performed with a specific protocol
resulting in an ablation zone of ∼1 cm diameter (Fig. 1).
Potential complications are rare and include iatrogenic dam-
age to the surrounding nerve root or tissues due to the elec-
trode placement, heat effect and size of the bone necrosis [6].
Follow-up of successful ablation is performed clinically and
there is no need for imaging follow-up in asymptomatic
patients [6].
Traditional surgical techniques for osteoid osteoma treat-
ment include wide excision removing a bone block, marginal
resection of the entire nidus, curettage or high-speed burr
techniques [40]. Comparison of these techniques to percuta-
neous, minimally invasive, imaging-guided ablation favours
the latter in terms of minimum trauma, minimum functional
restriction and significantly lower cost [40].
Thermal ablation can be used as a treatment in a
variety of benign tumours including osteoblastoma
(<3 cm in diameter) (Fig. 2) and chondroblastoma, whilst
throughout the literature there are reports of ablation in
cases of chondromyxoid fibroma, intracortical chondroma,
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aneurysmal bone cyst, eosinophilic granuloma and cystic
hydroma [2, 6, 41–43]. State-of-the-art reviews report that
“essentially any small well defined lesion at imaging can
be treated with RF ablation” [6].
Recent studies upon cryoablation report promising prelim-
inary results whenever the technique is applied as the treat-
ment in extrabdominal desmoids tumours [44, 45]. This kind
of treatment for soft tissue tumours seems to be governed by
Fig. 1 Osteoid osteoma in the tibia: a CT axial scan: metallic markers
were placed on the patient’s skin. bCTaxial scan: Once the trocar reaches
the lesion, the needle is removed and a bone biopsy needle is inserted
coaxially for sampling to verify the diagnosis. c CT axial scan: Then, the
radiofrequency electrode is inserted into the lesion coaxially and an
ablation protocol specific for osteoid osteoma is performed. d CT axial
scan: Follow-up post trocar removal. Notice the trocar tract, which ends
up in the lesion
Fig. 2 Osteoblastoma in the L2-
L3 facet joint: a CT axial scan: A
22G spinal needle is inserted
inside the epidural space and air is
injected through the antimicrobial
filter. b Axial CT scan: A trocar is
drilled till the lesion. c Axial CT
scan: Coaxially, a bipolar
radiofrequency electrode is
introduced inside the lesion and
the ablation protocol is
performed. d During the ablation
protocol, evoked potentials are
used for nerve monitoring
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high efficacy concerning local tumour control and pain reduc-
tion and at the same time by the reduced complication rate and
convalescence rate post-therapeutically [44, 45].
Malignant tumours
The most common malignant bone tumours are metastatic
lesions; any malignant neoplasm possesses the capacity to
metastasise in the musculoskeletal system [46]. In the general
population carcinomas of the breast, prostate, lung and kidney
constitute, in decreasing order, ∼75 % of skeletal metastasis
cases whilst carcinomas of the prostate, lung and bladder are
more common in males and carcinomas of the breast and
uterus more common in females [46]. Osseous metastatic
disease especially when lytic lesions are involved can result
in significant pain and mobility impairment. In most cases the
therapeutic goal is palliation with resultant pain reduction and
mobility improvement. Alternative therapeutic goals in palli-
ative treatments include tumour reduction/decompression and
bone consolidation. Potential therapies include surgery, em-
bolisation, chemotherapy, osteoplasty, ablation, radiotherapy
and palliative analgesics. External beam radiotherapy seems
to provide at least partial pain relief in 50 % and 80 % of
patients with only 30 % reporting complete pain relief [47]. In
addition, radiotherapy may result in osteonecrosis or neural
damage [48].
Apart from completely eliminating small oligometastatic
disease (<3 lesions each measuring <3 cm in diameter), abla-
tion is mainly used for achieving pain reduction to necrotise
the interface between the tumour and the pain-sensitive peri-
osteum [2, 3, 5, 6]. Alternative pathophysiologic explanations
for pain reduction post ablation include decompression of the
tumour volume, a decrease in nerve-stimulating cytokines
released by the tumour and inhibition of osteoclast activity
[8, 49]. Proper patient selection cannot be emphasised
enough; since ablation is a local therapy only patients with
localised, at least moderate (>4/10 numeric visual scale units)
pain should be treated. Absolute contraindications include
coagulopathy disorders, skin infection, immunosuppression
and the absence of a safe path to the lesion [50].
Percutaneous ablation of malignant metastatic lesions is
performed under imaging guidance, extended local sterility
measures and antibiotic prophylaxis. Whenever the ablation
zone is expected to extend up to 1 cm close to critical struc-
tures (e.g. the nerve root, skin, etc.), all the necessary thermal
protection techniques should be applied (Fig. 3).
Recent reviews and studies on ablation report promising
results whenever the technique is applied as treatment in
secondary lesions located in the soft tissues resulting in local
tumour control and pain reduction with reduced complication
rates and convalescence rates post-therapeutically [8, 45,
50–53]. Similarly, studies in the literature on percutaneous
ablation (RFA, MWA, MR-guided HIFU and cryoablation)
of metastatic painful bony lesions report significant pain re-
duction with minimal complications (Fig. 4) [11, 51–53]. To
date, there seems to be no difference in the efficacy of one
technique over the other [9].
A recent application of ablation techniques, more specifi-
cally of HIFU, is its use as a limb-salvaging treatment in
patients with osteosarcoma with resultant changes in symp-
toms and survival time [54]. However, further and more
extended studies are necessary for confirmation.
The cost of tumour necrosis in bone lesions treated with
ablation techniques is bone weakening. In order to avoid post-
therapeutic osteonecrosis with pathologic fractures, cement
augmentation should be combined with ablation especially
in the spine and other weight-bearing areas [2, 3, 5, 6, 8, 9,
50, 55]. Furthermore, in certain locations, due to the direction
of the forces applied upon weight bearing, cement augmenta-
tionmight be insufficient and should be combinedwith further
augmentation with metallic instrumentation; preliminary stud-
ies upon such combinations report very promising results
[56–58]. Whenever combining ablation with cementation at
the same session, it is necessary to allow enough time for the
tumour temperature to return back to normal in order to avoid
untimely cement polymerisation [50].
In order to enhance local tumour control, ablation can be
combined with transarterial chemoembolisation as well (espe-
cially for hypervascular lesions usually originating from thy-
roid, renal cell or hepatocellular carcinomas) [59, 60].
Whenever combining ablation with TACE or any other em-
bolisation technique, the intravascular technique usually pre-
cedes the ablation with/without cement augmentation [50].
Protective techniques
Protective measures include various techniques of insulation
and temperature or nerve function monitoring aiming at
protecting vulnerable structures. Passive thermal protection
techniques include continuous monitoring of the temperature
in the area of interest by thermocouples or of nervous function
by monitoring systems such as neurodiagnostic EEG, EMG
and evoked potential electrodes with accessories [61, 62].
Measurement of the temperature in proximity to a neural
structure or of the nerve’s functional ability during the ablation
provides valuable information for a safe and efficient session.
Heating over 45 °C or cooling below 10 °C can be neurotoxic
to the spinal cord and the peripheral nerves [2].
Active thermal protection techniques include gas dissec-
tion, hydrodissection and warming/cooling modes for skin
protection (subcutaneous fluid injection, application of a ster-
ile glove with warm or cold saline).
During gas dissection, CO2 or air is injected by means of a
22G spinal needle for dissecting vulnerable structures away
from the ablation zone. CO2 is a better insulator than air,
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which is less soluble and might result in emboli formation [61,
62]. For both gases use of an antimicrobial filter is optional.
Dissection by gas is not governed by heating or cooling
properties but it is only used in order to increase the distance
between the ablation zone and a certain structure [61, 62]. In
addition, during the ablation session the injected gas might be
absorbed and therefore additional injection might be needed.
Gas dissection is the active insulation of choice whenever
cryoablation is performed and in most cases of microwave
ablation. Gas dissection increases the distance between the
expected ablation zone and close nerve structures; in addition,
it is more commonly preferred over fluid dissection
whenever a spinal or paraspinal lesion is to be ablated
and the ablation zone is expected to extend near the
epidural space.
Fluid dissection creates the distance necessary for a safe
ablation zone, provides cooling or warming (depending on the
fluid’s temperature) as well as an occasional insulating effect.
In bone and soft tissue ablation this technique can be used in
epidural (nerve protection) or articular (cartilage protection)
spaces. In addition, it can increase the distance between the
expected ablation zone and a close nerve structure. For in-
creased visualisation a small amount of contrast medium can
be diluted in the fluid [61, 62]. Whenever fluid dissection is
required in ablation performed by radiofrequency energy,
dextrose in water (D/W 5 %) is preferred over saline solution
because of the latter’s high electrical conductivity [61, 62].
For microwave ablation, any fluid can be used as long as it is
distributed at least 2 cm away from the active tip of the
antenna. Fluid dissection cannot be used in cryoablation be-
cause the used fluid freezes when it comes in contact with the
ice ball.
If ablating superficial tumours the skin should be protected
in order to avoid and prevent painful burns or frostbite. Skin
seems to tolerate low better than high temperatures [61, 62].
Techniques for preventing skin lesions during ablation include
positioning sterile gloves containing warm or cooled fluid
over the expected ablation zone (for cryoablation and RFA/
MWA respectively). In addition, subdermal injection of local
Fig. 3 a Painful soft tissue mass infiltrating the left T10 posterior rib. bA
microwave antenna is percutaneously inserted inside the mass. Due to the
proximity to the skin a sterile glove filled with cold water is placed over
the skin. c CT axial scan 3 months after the ablation session: Notice the
significant size reduction of the mass along with new bone formation
around the left T10 posterior rib (similar to heterotopic ossification)
Fig. 4 Melanoma metastasis in the right iliac bone: Cryoablation was
performed with five cryoprobes inserted; notice how the iceball is
visualised on the CT scan as a hypodense structure
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anaesthetic or D/W 5 % increases the distance between the
ablation zone and skin.
Conclusion
Percutaneous ablation techniques constitute a safe and effica-
cious minimally invasive therapy for the treatment of osteoid
osteoma and an attractive adjunct in the therapeutic armamen-
tarium of small benign lesions or of oligometastatic bone
disease. In addition, thermal ablation can act as palliative
therapy in the rest of the cases. Primary or metastatic malig-
nant bone lesions (especially osteolytic) can become very
painful. The therapeutic armamentarium includes conserva-
tive therapy (analgesics), surgery, chemotherapy, radiothera-
py, embolisation, ablation and cementation. External beam
radiotherapy, although used frequently, provides moderate
pain relief. Tumour necrosis by means of percutaneous abla-
tion techniques seems an effective, safe and feasible technique
for the treatment of painful bony lesions. Ablation (RFA,
MWA, cryoablation) can treat such lesions and provide local
tumour control, performed either alone or in combination with
surgical resection or other percutaneous techniques.
Specifically for the spine and other weight-bearing locations,
ablation should be combined with cement augmentation and
occasionally also with further augmentation with metallic
instrumentation (which can also be percutaneous). Protection
of surrounding sensitive or critical structures is necessary
whenever the ablation zone is expected to extend close to
these structures. Thorough knowledge of each ablation tech-
nique and of all available protective techniques (both passive
and active, and in addition how they can be combined) is
mandatory for a safe and successful procedure.
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